Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2015 Apr 30;8:171. doi: 10.1186/s13104-015-1135-7

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Tzoulis et al.; licensee BioMed Central. 2015

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

PMC Copyright notice

Treatment response. Left panel: Sagittal imaging of the spinal cord tumor at the level of the 2nd-7th thoracic vertebrae by T2-weighted MRI (upper row), T1-weighted, gadolinium enhanced MRI (middle row) and fusion with FDG-PET (lower row) taken at baseline (A), one month (B) and three months (C) of vemurafenib therapy. There is gradual regression of the intramedullary tumor’s size, edema (T2 signal) and contrast-enhancement. PET shows complete disappearance of FDG uptake in the tumor and substantial reduction in the bodies of the 6th and 7th thoracic vertebrae. Right panel: whole body FDG-PET taken at the same time points showing gradual regression of hot-spots in the patient’s skeleton and in particular the lower limbs.